About

Bioquark, Inc. is focused on the development and commercialization of a novel range of biologic based products and services that have the ability to alter the biological regulatory state of human tissues and organs, with the goal of curing a wide range of diseases.

The biologic regulatory states of our cells, tissues and organs represent the central control processes behind our health (as well as our unfortunate transition towards disease, degeneration and aging), and a technology / product platform that can reverse negative transitions, will be transformational in the pharmaceutical industry, as well as in the wider healthcare business segment.

The company’s core program focuses on developing a novel class of substances termed combinatorial biologics, which take a unique approach to reversing underlying disease, degeneration or aging processes, as opposed to affecting the symptoms of such conditions, as most marketed pharmaceutical products currently do today.

Combinatorial biologics, which work at the level of the regulatory genome, and are modeled off of biochemical dynamics found in various species which can naturally modify biologic regulatory state to achieve beneficial endpoints such as complex tissue and organ regeneration, disease reversion, and even biological age reversal.

With annual healthcare expenditures for conditions that either have an underlying cellular degeneration or damage component, now surpassing $7 trillion globally, Bioquark’s platform makes the company an attractive candidate for high-value strategic transactions.  As such, Bioquark Inc. intends to take a multi-faceted strategy to leverage the development and commercialization potential of these unique bioactive materials.